Artan Biotechnologies LLC has closed a $1 million seed round to support progression of the company’s proprietary mutation-specific codon suppression platform toward first-in-human development.
Aptevo Therapeutics Inc. has been awarded a $1.5 million research grant from the Andy Hill Cancer Research Endowment (CARE) Fund to support IND-enabling work for APVO-451, Aptevo’s trispecific antibody-like immunotherapy candidate for solid tumors.
Flare Therapeutics Inc. has closed an $85 million series C financing and completed a strategic review of its pipeline, with funds being channeled to advance the prioritized programs.
Telum Therapeutics SL has completed an €18 million (US$24 million) series A financing to advance its lead program targeting hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by the multidrug-resistant gram-negative pathogen Acinetobacter baumannii.
Smartbax GmbH has announced the successful second closing of its pre-series A financing round for a total of €6.3 million (US$7.2 million) as it advances development of next-generation antibiotics against multidrug-resistant bacteria.
A year and a half from its formation, Oblenio Bio has generated positive nonhuman primate data for LBL-051 in chronic autoimmune diseases and closed a $62 million series B to move the trispecific T-cell engager into the clinic.
RQ Biotechnology Ltd. has completed an oversubscribed $115 million (£85.5 million) series A financing to advance its long-acting antibody therapeutics for the prevention of influenza in high-risk and immunocompromised populations.
X-tosis Inc. has been awarded a $2.74 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support advancement of XTS-001, the lead candidate from the company’s Mitoxts platform, toward clinical development for the treatment of Parkinson’s disease. The grant will support confirmatory studies, biomarker development and IND-enabling work.
Replicate Bioscience Inc. has been awarded a new grant worth approximately $3 million from the Gates Foundation to accelerate the development of globally accessible tuberculosis (TB) vaccines using Replicate’s clinically validated self-replicating RNA (srRNA) platform.
RSS
